BioNTech : and Pfizer Climb After Covid-19 Vaccine Wins U.K. Authorization

By Maria Armental

BioNTech SE trades near record levels following U.K. health regulator's emergency-use authorization for a Covid-19 vaccine developed by the German company and Pfizer Inc.

The approval clears the way for the two-shot vaccine to be distributed in limited numbers in the U.K. within days.

BioNTech shares, which traded as high as $123.59 on Wednesday, recently traded at $121.23, up 6% for the day and near the $124.24 closing record set on Nov. 30, according to FactSet.

Pfizer, meanwhile, traded 3.5% higher at $40.78.

A panel of experts advising the Food and Drug Administration is slated to review the vaccine on Dec. 10. The FDA could authorize soon after, and supplies should become available not long after that. Pfizer has already started shipping shots to distribution sites.

Write to Maria Armental at [e-mail]

(END) Dow Jones Newswires

12-02-20 1338ET